Possible Breakthrough in Cardiovascular Disease Diagnostics for Europe and the European Union
SINGAPORE,Dec. 16, 2022/PRNewswire/ -- Neuome Peptides Pte. Ltd., aSingapore-based company has established an assay-developmentplatform, powered bymachine learningandnovel, patented algorithmsfor thequantifiabledetection of biomarkers.
The company successfullydesigned specific peptidesto bind to pre-established,proven biomarkers for Cardiovascular Diseasesand is currently developingeffective diagnostic assays。The use of small peptides, conjugated with gold nanoparticles, allows a balance of high specificity and sensitivity, givinghighly accurate and fast results。
据欧元pean Heart Network, each year cardiovascular disease causes3.9 million deaths inEuropeandover 1.8 million deaths in the European Union。
This is made possible with the productTruHeart™, a point-of-care assay todiagnose Acute Coronary Syndromethat can givequantifiableresults within3-5 minutes, using afinger-pricksample to test for thecrucialbiomarkers,Troponins I and T, andMyoglobin(eventually expanding toD-DimerandBrain Natriuretic Peptide). It is in the advanced stages of R&D and progressing toglobal clinical trials。It will be submitted for FDA approval and then introduced to the market upon approval.
This product could be a game-changer, allowing patients to affordably screen for this potentially deadly conditionconveniently early, in their own home, achievingquantifiableresultswithout needing a laboratory。This more efficiently guides patients to seek appropriate medical attention; those with prevailing heart conditions may alsoregularlymonitor their conditionat home。In comparison to industry standards, it will beuniquely affordable; its peptide-coated cartridges will costonly~USD$2, while the quantitative electronic reader will cost~USD$80。This is incontrastto existing point-of-care devices also giving quantitative results for cardiac biomarkers, but at device costs of up toUSD$4,500,with cartridges ranging fromUSD$18-37。
The company's Scientific Advisory Board includes prominent leaders in this field, such asPadmashri Balram Bhargava,former Director General Indian Council of Medical Research (ICMR). The company has scheduledclinical trialsin five hospitals inIndia(including the renownedNarayanaHrudayalaya), in the process of securing a large site in the US and five sites inEurope。It is also advanced discussions withA*StarandSingapore'sNational Heart Centre.This is only one of many pipeline products made possible by its patented method of peptide-design. The immediate pipeline includes assays forProstate and Colorectal Cancers,Dengue, Malaria, and more.
About Neuome Peptides
It specializes in using a peptide-based approach to disrupt and democratize the diagnostics industry with affordable devices, able to provide lab-quality results in a fraction of the time and at a fraction of the cost. In line with its motto, "Convergence of Science" that integrates elements of life sciences, nanotechnology, electronics, and AI/machine learning in its products. The company is aware of the cost-inefficiencies of existing diagnostic solutions, therefore, the mission is to develop accurate, efficient and affordable diagnostic solutions to prevalent global health issues.
Learn more about TruHeart™:https://neuomepeptides.com/truheart/
Photo -https://mma.prnewswire.com/media/1968350/TruHeart_04.jpg
Logo -https://mma.prnewswire.com/media/1968342/NeuomePeptides_newLogo__1_Logo.jpg
SOURCE Neuome Peptides Pte. Ltd.
Share this article